318 related articles for article (PubMed ID: 19569180)
61. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
62. Ninein-like protein is overexpressed in head and neck squamous cell carcinoma and contributes to cancer growth and resistance to apoptosis.
Yu L; Song Y; Zhang Q; Zhan Q
Oncol Rep; 2009 Oct; 22(4):789-98. PubMed ID: 19724857
[TBL] [Abstract][Full Text] [Related]
63. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
[TBL] [Abstract][Full Text] [Related]
64. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
65. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Martens-de Kemp SR; Nagel R; Stigter-van Walsum M; van der Meulen IH; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Clin Cancer Res; 2013 Apr; 19(8):1994-2003. PubMed ID: 23444224
[TBL] [Abstract][Full Text] [Related]
66. Theraputic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC.
Yilmaz T; Jiffar T; de la Garza G; Lin H; Milas Z; Takahashi Y; Hanna E; MacIntyre T; Brown JL; Myers JN; Kupferman ME
Cancer Biol Ther; 2010 Sep; 10(6):644-53. PubMed ID: 20703101
[TBL] [Abstract][Full Text] [Related]
67. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
68. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
[TBL] [Abstract][Full Text] [Related]
69. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.
Zhou Y; Zhang L; Pan H; Wang B; Yan F; Fang X; Munnee K; Tang Z
PLoS One; 2015; 10(4):e0123208. PubMed ID: 25915207
[TBL] [Abstract][Full Text] [Related]
70. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Gelbard A; Garnett CT; Abrams SI; Patel V; Gutkind JS; Palena C; Tsang KY; Schlom J; Hodge JW
Clin Cancer Res; 2006 Mar; 12(6):1897-905. PubMed ID: 16551875
[TBL] [Abstract][Full Text] [Related]
71. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
72. Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma.
Aminuddin A; Ng PY; Leong CO; Chua EW
Sci Rep; 2020 May; 10(1):7885. PubMed ID: 32398775
[TBL] [Abstract][Full Text] [Related]
73. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
[TBL] [Abstract][Full Text] [Related]
74. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
75. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
76. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma.
Nakatani K; Wada T; Nakamura M; Uzawa K; Tanzawa H; Fujita S
J Cancer Res Clin Oncol; 2005 Jul; 131(7):445-52. PubMed ID: 15856296
[TBL] [Abstract][Full Text] [Related]
77. [Molecular mechanisms of chemoresistance in head and neck squamous cell carcinoma].
Zhao YX; Sun ZF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 31(11):888-891. PubMed ID: 29775010
[TBL] [Abstract][Full Text] [Related]
78. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma.
Gonzalez HE; Gujrati M; Frederick M; Henderson Y; Arumugam J; Spring PW; Mitsudo K; Kim HW; Clayman GL
Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):754-9. PubMed ID: 12874078
[TBL] [Abstract][Full Text] [Related]
79. Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.
Roy S; Kar M; Roy S; Saha A; Padhi S; Banerjee B
Cell Oncol (Dordr); 2018 Apr; 41(2):185-200. PubMed ID: 29243047
[TBL] [Abstract][Full Text] [Related]
80. Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Liu CW; Hua KT; Li KC; Kao HF; Hong RL; Ko JY; Hsiao M; Kuo ML; Tan CT
Mol Cancer Ther; 2017 Jul; 16(7):1421-1434. PubMed ID: 28265008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
